A recent article from the University of Wisconsin highlights ongoing progress in fibrolamellar carcinoma (FLC) research led by Dr. Sean Ronnekleiv-Kelly, a surgical oncologist focused on improving outcomes for this ultra-rare liver cancer.

Dr. Ronnekleiv-Kelly’s work centers on understanding how these tumors develop and identifying potential treatment targets. His lab studies patient tumors and pre-clinical models to better define the biology of the disease and where it may be vulnerable to therapy.

This research has been supported over several years by grants from FCF. Through this funding, his group has helped identify pathways—such as CDK7 activity—that may play a role in tumor growth and are being explored as therapeutic targets.

Recent research from his team and collaborators continues to build on these findings, contributing to a growing body of work aimed at developing more effective treatments for FLC.

The full article can be read here.